1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-2572.

2. Langman MJ, Lancashire RJ, Cheng KK, Stewart PM. Systemic hypertension and glaucoma: mechanisms in common and co-occurrence. Br J Ophthalmol. 2005;89: 960-963.

3. Phillips CI, Howitt G, Rowlands DJ. Propranolol as ocular hypotensive agent. Br J Ophthalmol. 1967;51:222-226.

4. Cote G, Drance SM. The effect of propranolol on human intraocular pressure. Can J Ophthalmol. 1968;3:207-212.

5. Bucci MG, Missiroli A, Giraldi JP, Virno M. Local administration of propranolol in the treatment of glaucoma. Boli Oculist. 1968;47:51-80.

6. Musini A, Fabbri B, Bergamaschi M, et al. Comparison of the effect of propranolol, lignocaine, and other drugs on normal and raised intraocular pressure in man. Am J Ophthalmol. 1971;72:773-781.

7. Zimmerman TJ, Kaufman HE. Timolol: a beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95:601-604.

8. Wettrell K, Pandolfi M. Early dose response analysis of ocular hypotensive effects of propranolol in patients with ocular hypertension. Br J Ophthalmol. 1976;60:680-683.

9. Wettrell K, Pandolfi M. Propranolol vs acetazolamide: a long-term double-masked study of the effect on intraocular pressure and blood pressure. Arch Ophthalmol. 1979;97:280-283.

10. Ohrstrom A, Pandolfi M. Long-term treatment of glaucoma with systemic propranolol. Am J Ophthalmol. 1978;86:340-344.

11. Wettrell K, Pandolfi M. Effect of oral administration of various beta-blocking agents on the intraocular pressure in healthy volunteers. Exp Eye Res. 1975;21:451-456.

12. Rahi AH, Chapman CM, Garner A, Wright P. Pathology of practolol-induced ocular toxicity. Br J Ophthalmol. 1976;60:312-323.

13. Skegg DC, Doll R. Frequency of eye complaints and rashes among patients receiving practolol and propranolol. Lancet. 1977;2:475-478.

14. Elliot MJ, Cullen PM, Phillips CI. Ocular hypotensive effect of atenolol (Tenormin, I.C.I.): a new beta-adrenergic blocker. Br J Ophthalmol. 1975;59:296-300.

15. MacDonald MJ, Cullen PM, Phillips CI. Atenolol versus propranolol: a comparison of ocular hypotensive effect of an oral dose. Br J Ophthalmol. 1976;60:789-791.

16. Bonomi L, Steindler P. Effect of pindolol on intraocular pressure. Br J Ophthalmol. 1975;59:301-303.

17. el-Sharaf ED, Haroun EA, Ishaac Z, et al. The effect of some beta-adrenergic blockers on human intraocular pressure. Exp Eye Res. 1974;19:223-225.

18. Rennie IG, Smerdon DL. The effect of a once-daily oral dose of nadolol on intraocular pressure in normal volunteers. Am J Ophthalmol. 1985;100:445-447.

19. Blondeau P, Cote M, Tetrault L. Effect of timolol eye drops in subjects receiving systemic propranolol therapy. Can J Ophthalmol. 1983;18:18-21.

20. Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology. 2000;107:1171-1177.

21. Ohrstrom A, Kattstrom O. A combination of oral and topical beta-blockers with additive effects on intraocular pressure. Acta Ophthalmol. 1983;61:1021-1028.

22. Makabe R. Ophthalmological studies with dichlorophenylamino-imidazoline. Dtsch Med Wochenschr. 1966;91:1686-1688.

23. Hasslinger C. Catapresan (2-(2,6-dichlorphenylamino)-2-imidazoline-hydrochloride): a new intaocular pressure lowering agent. Klin Monatsbl Augenheilkd. 1969;154:95-105.

24. Heilmann K. Examinations of the effect of Catapres in intraocular pressure. Klin Monatsbl Augenheilkd. 1970;157:182-192.

25. Hoskins HD Jr, Kass MA. Adrenergic agonists. In Hoskins HD Jr, Kass MA, eds. Becker-Schaffer's Diagnosis and Therapy of the Glaucomas. 6th ed. St Louis, MO: CV Mosby Co; 1989:435-452.

26. Liu JH, Neufeld AH. Study of central regulation of intraocular pressure using ven-triculocisternal perfusion. Invest Ophthalmol Vis Sci. 1985;26:136-143.

27. Netland PA. Calcium channel blockers in glaucoma therapy. Ophthalmol Clin North Am. 1997;10:357-364.

Kanellopoulos AJ, Erickson KA, Netland PA. Systemic calcium channel blockers and glaucoma. J Glaucoma. 1996;5:357-362.

Vanhoutte PM, Paoletti R. The WHO classification of calcium antagonists. Trends Pharmacol Sci. 1987;8:4-5.

Siegner SW, Giovanoni RL, Erickson KA, Netland PA. Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. J Ocul Pharmacol Ther. 1998;14:159-168. Green K, Kim K. Papaverine and verapamil interaction with prostaglandin E2 and A9-tetrahydrocannabinol in the eye. Exp Eye Res. 1977;24:207-212. Payne LJ, Slagle TM, Cheeks LT, Green K. Effect of calcium channel blockers on intraocular pressure. Ophthalmic Res. 1990;22:337-341.

Beatty JF, Krupin T, Nichols PF, Becker B. Elevation of intraocular pressure by calcium channel blockers. Arch Ophthalmol. 1984;102:1072-1076. Monica ML, Hesse RJ, Messerli FH. The effect of a calcium-channel blocking agent on intraocular pressure. Am J Ophthalmol. 1983;96:814.

Schnell D. Response of intraocular pressure in normal subjects and glaucoma patients to single and repeated doses of the coronary drug Adalat. In: Lochner W, Engel HJ, Lichtlen PR, eds. Second International Adalat Symposium. Berlin: Springer-Verlag; 1975:290-302.

Kelly SP, Walley TJ. Effect of the calcium antagonist nifedipine on intraocular pressure in normal subjects. Br J Ophthalmol. 1988;72:216-218.

Suzuki R, Hanada M, Fujii H, Kurimoto S. Effects of orally administered a-adrenergic blockers and calcium-channel blockers on the intraocular pressure of patients with treated hypertension. Ann Ophthalmol. 1992;24:220-223.

Erickson KA, Schroeder A, Netland PA. Verapamil increases outflow facility in the human eye. Exp Eye Res. 1995;61:565-567.

Abreu MM, Kim YY, Shin DH, Netland PA. Topical verapamil and episcleral venous pressure. Ophthalmology. 1998;105:2251-2255.

Pringle SD, MacEwen CJ. Severe bradycardia due to interaction of timolol eye drops and verapamil. BMJ. 1987;294:155-156.

Sinclair NI, Benzie JL. Timolol eye drops and verapamil: a dangerous combination. Med J Aust. 1983;1:548.

Hockwin O, Dragomirescu V, Laser H, et al. Evaluation of the ocular safety of ve-rapamil: Scheimpflug photography with densitometric image analysis of lens transparency in patients with hypertrophic cardiomyopathy subjected to long-term therapy with high doses of verapamil. Ophthalmic Res. 1984;16:264-275. Costagliola C, Di Benedetto R, De Caprio L, et al. Effect of oral captopril (SQ 14225) on intraocular pressure in man. Eur J Ophthalmol. 1995;5:19-25. Constad WH, Fiore P, Samson C, Cinotti AA. Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma. Am J Ophthalmol. 1988;105:674-677.

Wax MB, Burchfield JC, Lin C. Future directions for medical therapy of glaucoma. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. 2nd ed. St Louis, MO: CV Mosby Co; 1996:1489-1503.

Mandelkorn RM. Nonsteroidal drugs and glaucoma. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. 2nd ed. St Louis, MO: CV Mosby Co; 1996:1189-1204. Banta JT, Hoffman K, Budenz DL, et al. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol. 2001;132:112-114.

48. Sankar PS, Pasquale LR, Grosskreutz CL. Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch Ophthalmol. 2001;119:1210-1211.

49. Rhee DJ, Goldberg MJ, Parrish RK. Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol. 2001;119:1721-1723.

50. Medeiros FA, Zhang XY, Bernd AS, Weinreb RN. Angle-closure glaucoma associated with ciliary body detachment in patients using topiramate. Arch Ophthalmol. 2003;121:282-285.

51. Chen TC, Chao CW, Sorkin JA. Topiramate induced myopic shift and angle closure glaucoma. Br J Ophthalmol. 2003;87:648-649.

52. Craig JE, Ong TJ, Louis DL, Wells JM. Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma. Am J Ophthalmol. 2004;137:193-195.

53. Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology. 2004;111:109-111.

54. Hepler RS, Frank IM, Ungerleider JT. Pupillary constriction after marijuana smoking. Am J Ophthalmol. 1972;74:1185-1190.

55. Hepler RS, Frank IM. Marihuana smoking and intraocular pressure. JAMA. 1971;217:1392.

56. Hepler RS, Frank IM, Petrus R. Ocular effects of marihuana smoking. In: Braude MC, Szara S, eds. The Pharmacology of Marihuana. New York: Raven Press; 1976:815828.

57. Merritt JC, Crawford WJ, Alexander PC, et al. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980;87:222-228.

58. Green K, Roth M. Marijuana in the medical management of glaucoma. Perspect Ophthalmol. 1980;4:101-105.

59. Green K. Marijuana smoking vs cannabinoids for glaucoma therapy. Arch Ophthal-mol. 1998;116:1433-1437.

60. Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Trans Am Ophthalmol Soc. 2002;100:215-222.

61. Tiedeman JS, Shields MB, Weber PA, et al. Effect of synthetic cannabinoids on elevated intraocular pressure. Ophthalmology. 1981;88:270-277.

62. Zhan GL, Camras CB, Palmberg PF, Toris CB. Effects of marijuana on aqueous humor dynamics in a glaucoma patient. J Glaucoma. 2005;14:175-177.

63. Jay WM, Green K. Multiple-drop study of topically applied 1% A9-tetrahydro-cannabinol in human eyes. Arch Ophthalmol. 1983;101:591-593.

64. Obstbaum SA, Podos SM, Kolker AE. Low-dose oral alcohol and intraocular pressure. Am J Ophthalmol. 1973;76:926-928.

65. Peczon JD, Grant WM. Glaucoma, alcohol, and intraocular pressure. Arch Oph-thalmol. 1965;73:495-501.

66. Rhee DJ, Spaeth GL, Myers JS, et al. Prevalence of the use of complementary and alternative medicine for glaucoma. Ophthalmology. 2002;109:438-443.

67. Ritch R. Complementary therapy for the treatment of glaucoma: a perspective. Ophthalmol Clin North Am. 2005;18:597-609.

68. Rhee DJ, Katz LJ, Spaeth GL, Myers JS. Complementary and alternative medicine for glaucoma. Surv Ophthalmol. 2001;46:43-55.

69. West AL, Oren GA, Moroi SE. Evidence for the use of nutritional supplements and herbal medicines in common eye diseases. Am J Ophthalmol. 2006;141:157-166.

Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook

Post a comment